Literature DB >> 9096551

The effect of postmenopausal estrogen therapy on the risk of non-insulin-dependent diabetes mellitus.

L L Gabal1, D Goodman-Gruen, E Barrett-Connor.   

Abstract

OBJECTIVES: This study examined the effect of postmenopausal estrogen replacement therapy on the incidence of non-insulin-dependent diabetes in women.
METHODS: Postmenopausal women aged 50 through 70 years (n=848) without diagnosed diabetes at baseline were followed for 10 to 15 years for incident diabestes.
RESULTS: Over the average 11.5 year follow-ip, there were 105 new cases of diabetes. The age-adjusted relative-risk for development of diabetes was nonsignificantly lower for women with continuous estrogen replacement therapy use than for never users. After adjustment for major covariates, a nonsignificant linear trend with increasing duration of estrogen replacement therapy was reversed.
CONCLUSIONS: This study suggests that previous results showing a reduced risk of diabetes in women using estrogen may have been due to selection bias regarding who is prescribed estrogen, confounding factors, or differential diagnostic efforts.

Entities:  

Mesh:

Year:  1997        PMID: 9096551      PMCID: PMC1381022          DOI: 10.2105/ajph.87.3.443

Source DB:  PubMed          Journal:  Am J Public Health        ISSN: 0090-0036            Impact factor:   9.308


  15 in total

1.  Factors of risk in the development of coronary heart disease--six year follow-up experience. The Framingham Study.

Authors:  W B KANNEL; T R DAWBER; A KAGAN; N REVOTSKIE; J STOKES
Journal:  Ann Intern Med       Date:  1961-07       Impact factor: 25.391

2.  Estrogen replacement therapy II: a prospective study in the relationship to carcinoma and cardiovascular and metabolic problems.

Authors:  L E Nachtigall; R H Nachtigall; R D Nachtigall; E M Beckman
Journal:  Obstet Gynecol       Date:  1979-07       Impact factor: 7.661

3.  The Rochester Coronary Heart Disease Project: effect of cigarette smoking, hypertension, diabetes, and steroidal estrogen use on coronary heart disease among 40- to 59-year-old women, 1960 through 1982.

Authors:  C M Beard; T E Kottke; J F Annegers; D J Ballard
Journal:  Mayo Clin Proc       Date:  1989-12       Impact factor: 7.616

4.  The effect of estrogens on carbohydrate metabolism: glucose, insulin, and growth hormone studies on one hundred and seventy-one women ingesting Premarin, mestranol, and ethinyl estradiol for six months.

Authors:  W N Spellacy; W C Buhi; S A Birk
Journal:  Am J Obstet Gynecol       Date:  1972-10-01       Impact factor: 8.661

5.  Replacement estrogen use and body mass index.

Authors:  L A García Rodríguez; G M Pfaff; M C Schumacher; A M Walker; H Hoffmeister
Journal:  Epidemiology       Date:  1990-05       Impact factor: 4.822

6.  Sex differences in fasting glycemia as a risk factor for ischemic heart disease death.

Authors:  C Scheidt-Nave; E Barrett-Connor; D L Wingard; B A Cohn; S L Edelstein
Journal:  Am J Epidemiol       Date:  1991-03-15       Impact factor: 4.897

7.  The association of low levels of HDL cholesterol and arteriographically defined coronary artery disease.

Authors:  T A Pearson; B H Bulkley; S C Achuff; P O Kwiterovich; L Gordis
Journal:  Am J Epidemiol       Date:  1979-03       Impact factor: 4.897

8.  Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in U.S. population aged 20-74 yr.

Authors:  M I Harris; W C Hadden; W C Knowler; P H Bennett
Journal:  Diabetes       Date:  1987-04       Impact factor: 9.461

9.  Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study.

Authors:  T L Bush; E Barrett-Connor; L D Cowan; M H Criqui; R B Wallace; C M Suchindran; H A Tyroler; B M Rifkind
Journal:  Circulation       Date:  1987-06       Impact factor: 29.690

10.  Effects of low doses of transdermal 17 beta-estradiol on carbohydrate metabolism in postmenopausal women.

Authors:  A Cagnacci; R Soldani; P L Carriero; A M Paoletti; P Fioretti; G B Melis
Journal:  J Clin Endocrinol Metab       Date:  1992-06       Impact factor: 5.958

View more
  9 in total

1.  Menopausal hormone therapy and new-onset diabetes in the French Etude Epidemiologique de Femmes de la Mutuelle Générale de l'Education Nationale (E3N) cohort.

Authors:  B de Lauzon-Guillain; A Fournier; A Fabre; N Simon; S Mesrine; M-C Boutron-Ruault; B Balkau; F Clavel-Chapelon
Journal:  Diabetologia       Date:  2009-07-23       Impact factor: 10.122

2.  Current research in the epidemiology and public health of aging--the need for more diverse strategies.

Authors:  S V Kasl
Journal:  Am J Public Health       Date:  1997-03       Impact factor: 9.308

3.  Diabetes, diversity, and disparity: what do we do with the evidence?

Authors:  Sandra A Black
Journal:  Am J Public Health       Date:  2002-04       Impact factor: 9.308

Review 4.  Glycaemic control and hormone replacement therapy: implications of the Postmenopausal Estrogen/Progestogen Intervention (PEPI) study.

Authors:  S E Fineberg
Journal:  Drugs Aging       Date:  2000-12       Impact factor: 3.923

5.  Timing of Estradiol Treatment After Menopause May Determine Benefit or Harm to Insulin Action.

Authors:  R I Pereira; B A Casey; T A Swibas; C B Erickson; P Wolfe; R E Van Pelt
Journal:  J Clin Endocrinol Metab       Date:  2015-10-01       Impact factor: 5.958

Review 6.  Oestrogens and insulin secretion.

Authors:  I F Godsland
Journal:  Diabetologia       Date:  2005-09-29       Impact factor: 10.122

7.  Body fat distribution, menopausal hormone therapy and incident type 2 diabetes in postmenopausal women of the MESA study.

Authors:  Imo A Ebong; Karol E Watson; Kristen G Hairston; Mercedes R Carnethon; Pamela Ouyang; Moyses Szklo; Alain G Bertoni
Journal:  Maturitas       Date:  2016-06-28       Impact factor: 4.342

Review 8.  Influence of menopause on diabetes and diabetes risk.

Authors:  Emily D Szmuilowicz; Cynthia A Stuenkel; Ellen W Seely
Journal:  Nat Rev Endocrinol       Date:  2009-08-18       Impact factor: 43.330

9.  Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals.

Authors:  Meei-Shyuan Lee; Chih-Cheng Hsu; Mark L Wahlqvist; Hsin-Ni Tsai; Yu-Hung Chang; Yi-Chen Huang
Journal:  BMC Cancer       Date:  2011-01-18       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.